Catalyst Pharmaceutical (CPRX -6.6%) slides after announcing a collaboration agreement with...
Wednesday, October 31, 2012, 3:02 PM ETCatalyst Pharmaceutical (CPRX -6.6%) slides after announcing a collaboration agreement with BioMarin Pharmaceutical (BMRN -4.5%) for the North American rights to Firdapse, a treatment of Lambert-Eaton Myasthenic Syndrome. According to the agreement, CPRX will license exclusive rights to Firdapse, while BMRN will make a $5M investment in CPRX for program advancement. Firdapse is an orphan product that has already been approved in the E.U. and is undergoing phase III clinical trials in the U.S.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles